2021
Anti-inflammatory properties of ethanolic extract from Vatairea macrocarpa leaves
Santos E, Silva-Filho S, Santos Radai J, Arena A, Fraga T, Lima Cardoso C, Croda J, Leite Kassuya C. Anti-inflammatory properties of ethanolic extract from Vatairea macrocarpa leaves. Journal Of Ethnopharmacology 2021, 278: 114308. PMID: 34102271, DOI: 10.1016/j.jep.2021.114308.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnimalsAnti-Inflammatory AgentsBCG VaccineCarrageenanDexamethasoneDose-Response Relationship, DrugEthanolFabaceaeFemaleMaleMiceMice, Inbred C57BLPhytotherapyPlant ExtractsPlant LeavesPleurisyConceptsAnti-inflammatory propertiesMethylthiazolyldiphenyl-tetrazolium bromideComplete Freund's adjuvantAnti-inflammatory featuresEthanolic extractLong-term treatmentBacillus Calmette-GuerinInflammatory evaluationInflammatory parametersConventional medicationsDaily administrationNeutrophil activityPersistent inflammationRheumatic diseasesFreund's adjuvantInflammatory aspectsPleurisy modelTraditional folk medicineSwiss miceCalmette-GuerinInflammatory diseasesC57BL6 miceVivo modelExperimental modelAdverse effects
2020
Blutaparon portulacoides ethanolic extract reduced IL-1β and inflammatory parameters induced by the Mycobacterium complex and carrageenan in mice
Kassuya R, Radai J, Macorini L, Nunes V, Salvador M, Leite P, Oliveira R, Croda J, Arena A, Kassuya C. Blutaparon portulacoides ethanolic extract reduced IL-1β and inflammatory parameters induced by the Mycobacterium complex and carrageenan in mice. Inflammopharmacology 2020, 29: 439-450. PMID: 32910315, DOI: 10.1007/s10787-020-00752-0.Peer-Reviewed Original ResearchMeSH KeywordsAmaranthaceaeAnimalsAnti-Inflammatory AgentsAntitubercular AgentsCarrageenanDisease Models, AnimalDose-Response Relationship, DrugEdemaFemaleInflammationInterleukin-1betaMaleMiceMice, Inbred C57BLMicrobial Sensitivity TestsMycobacterium tuberculosisPlant ExtractsPleurisyRatsRats, WistarConceptsSwiss miceIL-1β levelsC57BL-6 miceEthanolic extractInflammation/infectionSafe new drugsM. tuberculosis growthMechanical hyperalgesiaInflammatory parametersOral treatmentIL-1βPleurisy modelMinimum inhibitory concentrationPharmacoeconomic perspectiveC57BL6 miceComplete adjuvantSubcutaneous injectionOral administrationWistar ratsMiceMycobacterium tuberculosisNew drugsHealth benefitsTuberculosis growthInhibitory concentrationEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M, Mourão M, Brito-Sousa J, Baía-da-Silva D, Guerra M, Hajjar L, Pinto R, Balieiro A, Pacheco A, Santos J, Naveca F, Xavier M, Siqueira A, Schwarzbold A, Croda J, Nogueira M, Romero G, Bassat Q, Fontes C, Albuquerque B, Daniel-Ribeiro C, Monteiro W, Lacerda M. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open 2020, 3: e208857. PMID: 32330277, DOI: 10.1001/jamanetworkopen.2020.8857.Peer-Reviewed Original ResearchConceptsHigh dosage groupSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionLow dosage groupSyndrome coronavirus 2 infectionCoronavirus 2 infectionChloroquine diphosphateDay 13COVID-19Phase IIb clinical trialNonsevere COVID-19Secondary end pointsSevere COVID-19High-dose groupSpecific antiviral therapyTertiary care facilityIIb clinical trialCoronavirus disease 2019More heart diseaseParticipants' clinical statusAdjunctive therapyAdult patientsIll patientsPrimary outcomeAntiviral therapy
2016
Anti-inflammatory, antioxidant and anti-Mycobacterium tuberculosis activity of viridiflorol: The major constituent of Allophylus edulis (A. St.-Hil., A. Juss. & Cambess.) Radlk.
Trevizan L, do Nascimento K, Santos J, Kassuya C, Cardoso C, do Carmo Vieira M, Moreira F, Croda J, Formagio A. Anti-inflammatory, antioxidant and anti-Mycobacterium tuberculosis activity of viridiflorol: The major constituent of Allophylus edulis (A. St.-Hil., A. Juss. & Cambess.) Radlk. Journal Of Ethnopharmacology 2016, 192: 510-515. PMID: 27612433, DOI: 10.1016/j.jep.2016.08.053.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsAntioxidantsAntitubercular AgentsBenzothiazolesBiphenyl CompoundsCarrageenanChemotaxis, LeukocyteDexamethasoneDisease Models, AnimalDose-Response Relationship, DrugEdemaFemaleGas Chromatography-Mass SpectrometryMaleMiceMycobacterium tuberculosisOils, VolatilePhytotherapyPicratesPlant ExtractsPlant LeavesPlant OilsPlants, MedicinalPleurisySapindaceaeSulfonic AcidsTerpenesTime FactorsConceptsNatural anti-inflammatory agentAnti-inflammatory agentsSubcutaneous injectionOral administrationAnti-Mycobacterium tuberculosis activityAnti-mycobacterial activityAntioxidant activityTotal leucocytesEOAETuberculosis activityMycobacterium tuberculosisGas chromatography-mass spectrometrySignificant inhibitionMiceTraditional medicineEdemaPleurisyPositive controlReference standardDexamethasoneCarrageenanAdministrationModerate antioxidant activityInjectionMajor constituents
2009
Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit
Croda J, Croda M, Neves A, dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Critical Care Medicine 2009, 37: 1605-1611. PMID: 19325488, PMCID: PMC4143892, DOI: 10.1097/ccm.0b013e31819da8c7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveBrazilCohort StudiesConfidence IntervalsCritical CareCritical IllnessDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHospital MortalityHumansIntensive Care UnitsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisConceptsIntensive care unitAntiretroviral therapyICU admissionCare unitChronic Health Evaluation II scoreHuman immunodeficiency virus-infected patientsCD4 T-cell countUse of ARTTertiary care teaching hospitalMultivariate logistic regression analysisCox proportional hazards modelAcute illness severityRetrospective cohort studyT-cell countsVirus-infected patientsDay of admissionHuman immunodeficiency virusCause of admissionProportional hazards modelPotential confounding factorsLogistic regression analysisAcute PhysiologyICU mortalityII scoreCohort study